What is HC Wainwright’s Forecast for Valneva Q1 Earnings?

Valneva SE (NASDAQ:VALN) – Research analysts at HC Wainwright issued their Q1 2025 EPS estimates for shares of Valneva in a report released on Thursday, January 23rd. HC Wainwright analyst E. White expects that the company will post earnings of ($0.38) per share for the quarter. HC Wainwright has a “Buy” rating and a $18.00 price objective on the stock. The consensus estimate for Valneva’s current full-year earnings is $0.15 per share. HC Wainwright also issued estimates for Valneva’s Q2 2025 earnings at ($0.29) EPS, Q3 2025 earnings at ($0.31) EPS and Q4 2025 earnings at ($0.31) EPS.

Valneva Trading Up 3.4 %

NASDAQ VALN opened at $4.90 on Friday. The stock has a market capitalization of $398.17 million, a price-to-earnings ratio of -37.69 and a beta of 1.93. Valneva has a one year low of $3.62 and a one year high of $9.50. The company has a debt-to-equity ratio of 0.70, a current ratio of 2.78 and a quick ratio of 2.25. The business’s fifty day moving average is $4.29 and its 200-day moving average is $5.78.

Institutional Investors Weigh In On Valneva

A hedge fund recently raised its stake in Valneva stock. AlphaCentric Advisors LLC boosted its position in Valneva SE (NASDAQ:VALN) by 33.7% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 118,000 shares of the company’s stock after acquiring an additional 29,748 shares during the period. AlphaCentric Advisors LLC owned 0.15% of Valneva worth $717,000 as of its most recent SEC filing. 11.39% of the stock is currently owned by institutional investors.

About Valneva

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.